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Abstract

Prenatal drug exposure is a common clinical phenomenon in pregnancy cases. Pregnancy is a
fragile period of time for both the mother and the fetus. Therefore, strict drug regulation is
important to ensure the safety and wellbeing of the developing fetus. Certain drugs, once thought
to be safe, have been found to have detrimental effects on the normal development of functioning
organ systems in the fetus. Current research has identified drugs that when taken during
pregnancy can result in the onset of fetal physical abnormalities, impaired brain development,
and disrupted organogenesis and organ function. Thalidomide, losartan, opioids, alcohol, and
caffeine are reviewed to identify the trends in the literature on prenatal drug exposure and the
implications of drug usage during pregnancy. Although the Food & Drug Administration (FDA)
are active in regulation, educational programs for pregnant/lactating women and epidemiological
research on both prescribed and over-the-counter drugs on the fetus is necessary to preserve
maternal health and, consequently, the health of the baby.
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Prenatal Drug Exposure and its Effects on Fetal Development: Clinical and Health
Education Implications
Pregnancy is one of the most dynamic stages of life for many women. When a woman
becomes pregnant, her body undergoes an extensive number of physiological changes which are
necessary to accommodate the growing baby. Critical and sensitive stages of development, most
of which are foundational for growth outside of the womb, occur during pregnancy; therefore,
any disruption to this process could detrimentally affect the overall health and wellbeing of the
fetus. For this reason, the successful development of the fetus becomes the predominant goal. To
accomplish this goal, the health of the mother is strictly monitored during pregnancy.
Specifically, prenatal nutrition, drug intake, and lifestyle are observed and consistently
supervised to facilitate a healthy pregnancy and normal fetal development. Prenatal drug
exposure is a clinical phenomenon that has impacted the lives of mothers and children around the
world. The NIH reported that about 5% of pregnant women use one or more addictive drugs as
of 2012; this statistic increased over the years (NIDA, 2021). In the 2018 National Survey of
Drug Use and Health, illicit drug use by pregnant women increased to 5.4% (SAMHSA, 2018).
This steady increase of drug use by pregnant women has become a critical public health concern
as more drugs have become more available to the public.
During pregnancy, drug intake/exposure is observed by the primary physician due to the
adverse effects certain drugs may have on the fetus (Konijnenberg, 2015). Current research has
found that major prescription and over-the-counter drugs that were considered to be safe,
especially for daily use, can cause adverse effects on fetal development. The FDA has
established a categorical index, and today, a new labeling system for pregnant women is used to
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determine which medication is safe to take; however, if not being urgently tested or monitored,
pregnant women are often left uneducated with respect to their medications and implications of
safety that should be considered prior to intake. This literature review aims to explore select
drugs that have been shown to adversely affect fetal development. The following drugs will be
reviewed: thalidomide, losartan, opioids, alcohol, and caffeine. Each drug discussed represents a
category established by the FDA that describes medications and their relative effects during
pregnancy (see Appendix A). The following analysis will also highlight the urgent need of
accurate testing/regulation to protect newborns from the onset of diseases and other dangerous
conditions.
Maternal Nutrition
The survival of the fetus is largely dependent on maternal health because pregnancy
accommodates the development of vital organ systems. The development of the integumentary
and musculoskeletal systems begin at gestation (Leung et al., 2013; Yan et al., 2013). The
epidermal layer of the skin continues to develop throughout pregnancy, and two layers, the basal
layer and periderm, are formed at the first four weeks. At nine weeks, the skin has been
keratinized; at thirteen weeks, the different layers that make up the skin can be differentiated
(Leung et al., 2013). While the skin develops throughout gestation, the musculoskeletal system is
developing consequently. During the embryonic stage, primary myogenesis occurs in which a
small amount of muscle fibers begins to form. When the embryo enters the fetal stage, these
muscle fibers serve as the framework for the additional muscle fibers that form which become
the musculoskeletal system (Yan et al., 2013). The proliferation of these muscle fibers heavily
relies on adequate nutrition. Fetal development is highly sensitive to maternal nutrient

PRENATAL DRUG EXPOSURE

6

deficiency, primarily during early gestation (Wu et al., 2012). If the mother is lacking nutrients
or does not have a healthy diet, the peri-implantation and placenta formation stages are easily
affected, resulting in the onset of disorders that hinder the growth of the fetus. Furthermore, the
musculoskeletal system is dramatically affected by the lack of nutrients (Wu et al., 2012; Yan et
al., 2013;). The diet of the mother, therefore, is incredibly important for the progression of
normal fetal development. Maternal nutrition affects all stages of pregnancy and the
development of all physiological systems. Diets composed of mostly sugar and fat are associated
with the development of metabolic and cardiovascular diseases later in life (Lowensohn et al.,
2016). Therefore, mothers are encouraged to have a diet rich in fruits, vegetables, grains, and fish
to maintain optimal health during pregnancy. Supplemental folic acid, calcium, and iodine are
also encouraged to protect against neural tube defects, asthma, and iodine deficiency. Nutrientdense foods are preferred over calorically dense foods to support the pregnancy and maintain a
healthy weight (Lowensohn et al., 2016). Maintaining this diet would prevent low birth weights
which are associated with fetal growth impairment and later occurrence of other metabolic
diseases.
Fetal Development
Organogenesis commences and progresses from weeks three to eight of gestation. The
digestive system of the fetus develops right after implantation of the blastocyst. After three
weeks, the digestive tube differentiates, and gastrulation occurs in which three germ layers
arise—mesoderm, endoderm, and ectoderm (Bhatia et al., 2021). The mesoderm later forms the
connective tissue and smooth muscle that will become the gut tube. The endoderm constitutes
the epithelial lining of the GI tract, pancreas, liver, and gall bladder which are essential for
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digestion and nutrient absorption. The ectoderm composes the surface ectoderm, neural tube, and
neural crest which gives rise to facial features, the brain and spinal cord, and the entirety of the
peripheral nervous system consequently (Bhatia et al., 2021). Additionally, the formation of the
respiratory system begins at the third week. The respiratory diverticulum is located posterior to
the pharynx and at the ventral wall of the primitive foregut formed by the endoderm. A parallel
tube, which later becomes the trachea anteriorly and esophagus posteriorly, is established after
the ventral wall of the foregut buds off the dorsal wall of the respiratory diverticulum (Rehman
& Bacha, 2021). By the fourth week, the caudal end of the trachea divides into the left and right
primary bronchial buds which will differentiate into secondary bronchial buds, leading to the
formation of the lobes of the lungs. Branching of these buds will continue until the end of the
sixth week. During the fifth to seventh weeks, the visceral and parietal pleura of the lungs are
constructed by the mesoderm. At the end of the embryonic stage, the trachea, larynx,
primordium, lobes, and the ten bronchopulmonary segments of the lungs are completely formed;
the lungs will continue to develop after birth (Rehman & Bach, 2021). While these two major,
interconnected systems are being constructed, brain development also occurs with the rise of the
three germ layers. During the third week, the neural progenitor cells divide into neurons and glia.
By the ninth week, the brain is a small structure that will continue to grow and begin to have
folds which are characteristic of certain brain regions (Konkel, 2018). This dramatic growth
occurs on a cellular level while certain signaling molecules assist in communication between
neurons. Later, the neocortex develops which is involved in senses, thought, reasoning, and
language. The brain continues to develop and grow after the child is born (Konkel, 2018). These
organ systems are only a portion of the systems that are being developed. However, each system
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is equally important and are required for normal functioning after prenatal development. When
the development of even one system is hindered, a resultant cascade of cellular changes can
occur that could change the course of the life of the fetus.
FDA Drug Categories for Pregnant Women
For years, a growing concern for the regulation of prescription medications for pregnant
women correlative to the discovery of more diseases and disorders has developed. In 1979, the
FDA created pregnancy-risk letter categories (A, B, C, D, and X) that aimed to help pregnant
women understand the risk of birth defects as a result of taking certain medications during
pregnancy. Category A includes drugs that have not been found to cause birth defects. Drugs in
category B are shown to have no adverse effects on the fetus in animal reproduction studies,
however no controlled studies on pregnant women have been published. Category C includes
drugs that have been found to cause birth defects in animal reproduction, but no controlled
studies on pregnant women have been conducted. Category D includes drugs that are a risk to the
human fetus. However, drugs in both categories C and D can still be used by pregnant women as
prescribed and monitored by a physician. Drugs in category X pose dangerous health risks to the
human fetus and are not prescribed to pregnant women in any case or during any term of
pregnancy (FDA, 2014). These categories were established for the safety of the mother and
child, however, the letter categories showed to be a cause of confusion when patients read the
label on their medications. Effective starting on June 30, 2015, the FDA replaced the letters with
a new system, called the Pregnancy and Lactation Rule, that clarifies not only the risks of
exposure during fetal development, but also the risks during breastfeeding, testing for pregnancy,
and fertility (FDA, 2014).The goals of this new rule are twofold; 1) to aid clinicians in
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prescribing medications and 2) to improve the accessibility of the risks and benefits of certain
drugs to the end of empowering pregnant and nursing women to make appropriate decisions
regarding their health and the health of their children. Although labelling changes are seemingly
miniscule in comparison to other forms of drug distribution regulations, it provides vital
information for both the clinician and the patient that will assist in understanding how to treat the
current condition of the mother. The effectiveness of this new regulation, however, requires time
to determine its helpfulness to both the patient and the clinician.
The Case of Thalidomide
The stringency of modern drug testing, especially for pregnant women, is a result of
modern research identifying links between drugs and certain disorders in developing children.
Thalidomide, a category X drug, is one of many drugs that, while effective, was later found to
pose a threat to proper fetal development. Thalidomide was introduced in the 1950s as a
sedative, anti-emetic, and treatment for nausea in pregnant women (Kim & Scialli, 2011;
Vargesson, 2015). It was globally marketed and distributed and resultantly became one of the
best selling drugs in history.
Dangerous Birth Defects caused by Thalidomide
The dangerous aftereffects of using thalidomide were made apparent when the children of
the thalidomide-using mothers were born; around 10,000 children were born with severe birth
defects because of its usage (Kim & Scialli, 2011; Vargesson, 2015;). One of the most prominent
outcomes of thalidomide exposure during fetal development is congenital malformation. In a
study conducted by Hallene et al. (2006), the effects of thalidomide exposure on neural
development of rat pups were studied. When exposed to thalidomide, the brain cortical thickness
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increased due to the onset of interstitial edema. Exposure also had acute effects on the formation
of cerebral blood vessels which decreased in the thalidomide-exposed group. Additionally, early
exposure to thalidomide was correlated to altered vasculogenesis and angiogenesis as seen in the
decreased growth of the bovine aortic endothelial cell tube and decrease in hemoglobin
concentration. Consequently, a decline in vascular endothelial growth factors was confirmed 48
hours after exposure to thalidomide. This inhibition of growth resulted in altered developing
cortexes characterized by cortical swelling, thicker cortexes, and edema. Postnatal effects include
abnormalities in vascular profiles and white matter distribution of the cortical and hippocampal
structures, leading to leaky vessels; these findings were observed 4-8 days after birth. The study
also found that thalidomide exposure is associated with microcephaly and an increased chance of
miscarriage or fetal resorption (Hallene et al., 2006). The changes in neuroarchitecture could also
affect the neural pathways being formed. In humans, this damage to the brain may lead to the
development of autism and epilepsy (Vargesson, 2015).
Thalidomide exposure is also associated with the onset of congenital heart disease.
Cardiac development is key for the formation of organs in the womb. This period of prenatal
development is considered one of the most sensitive stages (Kumar et al., 2018; Vargesson,
2015). Thalidomide intake during pregnancy was shown to correlate to heart abnormalities, such
as pulmonary stenosis, patent ductus arteriosus, ventricular septal defect , and atrial septal defect
(Smithells & Newman, 1992). A study performed by Kumar et al. (2018) utilized chick embryos
to identify the cardiac effects of thalidomide exposure. Lump formation in the heart wall was
prominent in the left ventricle later affecting cardiac looping. Continuous observation of the
lump had also shown that thalidomide led to blood hemorrhage. The lumps that were formed
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were non-muscular and resembled a blood clot containing a high concentration of hemoglobin.
When the tissue of the lump was isolated, the expression of immune genes was found to be
downregulated in the lump. Furthermore, the movement of cardiac progenitor cells (CPCs) was
inhibited by thalidomide. When RNA was isolated from the heart tissue, bcl2, a gene responsible
for regulating apoptosis, and Fgfr3, a growth factor involved in cardiac remodeling, are
upregulated; the tbx5 gene which is important for septum formation and coordination of heart
contractions is downregulated (Hardwick & Soane, 2013; Itoh & Ohta, 2013; Khalil et al., 2017;
Kumar et al. 2018). The unusual morphology in cardiac looping may have resulted from
inhibited migration of the CPCs in which apoptosis was induced. The study also indicated that
this looping defect may have led to unusual fluid pressure distribution that resulted in the
formation of the lump in the hearts of the chick embryos. Furthermore, the anatomical anomalies
may have also arisen from the inhibition of CPC migration which compromises cardiac wall
development (Kumar et al. 2018). Therefore, thalidomide is recognized as a cardiac teratogen.
The American Heart Association (as cited in Jenkins et al., 2007) released a statement
saying that during the period of gestation, there is no safe dose of thalidomide treatment for
pregnant women. Defects in the development of the limbs, eyes, ears, face, genitalia, vertebral
column, and/or internal organs were observed; this widespread effect of thalidomide use is now
termed thalidomide embryopathy. This critical condition can result in infant mortality because of
the damage present in the internal organs (Smithells & Newman, 1992; Vargesson, 2015).
Malformations of the urinary tract, kidneys, genitals, and gastrointestinal tract are associated
with thalidomide embryopathy. However, the rate of incidence of these defects are unknown due
to the inability to track the large number of affected individuals that were affected by the
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thalidomide phenomenon (Smithells & Newman, 1992; Vargesson, 2015). Notable defects that
are characteristic of this condition include small eyes, eyeball absence, and poor vision. Ocular
defects, such as aberrant coloboma and strabismus, are common in thalidomide survivors; some
survivors also report deafness and other hearing deficits (Smithells & Newman, 1992;
Vargesson, 2015). As found in heart formation, the tbx5 gene plays a vital role in teratogenicity
as it interacts with thalidomide. The drug binds to R81, R82, and K226, in the T-box domain
which is essential for the interaction of TBX5 with DNA. TBX5 is also heavily involved in limb
development during gestation; when bound to thalidomide, the gene is downregulated,
potentially leading to physical deformities in the developing fetus (Khalil et al., 2017). The
mechanism and effects of thalidomide binding on the gene for cardiac and limb development,
however, are still being studied. In 1961, the drug was eventually banned due to reports of
peripheral neuropathy and other birth defects in multiple organ systems (Vargesson, 2015).
Recent literature suggests that the window in which thalidomide exposure happens may be a
factor in determining the level of damage to the developing fetus (Kim & Scialli, 2011;
Vargesson, 2015). Although thalidomide causes significant damage during days 20-36 after
fertilization, recent studies indicate that the drug may not be safe during any period of gestation
with the increased incidence of miscarriage and subsequent organ damage (Khalil et al., 2017;
Kim & Scialli, 2011; Kumar et al., 2018; Smithells & Newman, 1992; Vargesson, 2015). The
dangerous aftermath of thalidomide changed the way drugs are tested, resulting in stricter drug
regulation and distribution especially for pregnant and reproductive-aged women. Despite the
grave effects of its use in the past, thalidomide has been shown to be an effective treatment for
leprosy, cancer, multiple myeloma, HIV, and other diseases. Its use as a treatment for these
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conditions is continuously being closely regulated and monitored to ensure the safety and wellbeing of those exposed to the drug; specifically, pregnant women are discouraged from
thalidomide intake (Rajkumar et al., 2003; Singhal et al., 1999; Vargesson, 2015). The case of
thalidomide is unique; however, it exemplifies the positive role of drug safety research and strict
drug regulation in the protection of the most vulnerable.
Losartan
As seen in the example of thalidomide, everyday drugs/medications have the potential to
be a danger for pregnant women if not exhaustively tested and strictly regulated. Losartan,
classified as a category D drug, is a common antihypertensive drug . The drug is a nonpeptide
angiostenin II (AII) receptor antagonist that will selectively bind to AT-1 receptors, lowering
blood pressure (Alwan et al., 2005; Goa & Wagstaff, 1996; Mata-Greenwood et al., 2018). AII is
a key player in the renin-angiotensin (RAS) system which regulates blood pressure in the body.
RAS also plays a vital role in the formation of intrauterine tissue, directly regulating
uteroplacental blood flow necessary for nutrient transport to the fetus (Lumbers & Pringle,
2014). Binding to AT-1 receptor is involved in increasing blood pressure and vasoconstriction,
however when inhibited, blood flow decreases which can be a major concern during pregnancy.
During the first few weeks of pregnancy, AT-2 receptors are more highly expressed than AT-1
receptors for kidney development; however, expression of AT-1 receptors increases during the
later stages of pregnancy (Alwan et al., 2005). The adverse effects of losartan and other AT-1
receptor antagonist treatment are more obvious during the second and third trimesters. One of the
main outcomes of losartan intake during pregnancy is the reduction of amniotic fluid which is
essential for protecting the fetus, lung development, and the formation of other organ systems.
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Before the fetal kidneys can secrete urine into the amniotic fluid, most of the fluid will be
coming from the maternal blood. Renal perfusion is low during the beginning of fetal
development. Therefore, when losartan inhibits the function of AT-1 receptors, fetal hypotension
and renal hypoperfusion may occur and blood flow decreases to the fetus. Furthermore, low
levels of amniotic fluid, below 5 cm, usually indicates a birth defect or maternal illness. When
the fetus experiences a prolonged inadequate amount of amniotic fluid that is required for being
in the gestational stage, the condition is called oligohydramnios (Alwan et al., 2005; Jabeen et
al., 2021; Rosenthal & Oparil, 2002). This decrease in amniotic fluid is due to the reduction of
urine output caused by the renal system being suppressed by losartan. A recent study found a low
pulsatility index (PI) for the middle cerebral artery and a high PI for the umbilical artery
associated with oligohydramnios, demonstrating redistribution of blood flow and possible brainsparing effects (Jabeen et al., 2021). The high PI value indicates impaired placentation and
increased risks for preeclampsia, abruption, fetal growth restriction, and stillbirth. Additionally,
in cases of isolated term oligohydramnios, maternal vascular malperfusion lesions occur at a
higher rate. Isolated term oligohydramnios is the condition in which amniotic fluid in the womb
is reduced at term in the absences of fetal growth restriction, maternal illness, or chromosomal
irregularities (Miremberg et al., 2020; Rosenthal & Oparil, 2002). Therefore, the womb becomes
more toxic for the developing fetus. Due to the imbalance of blood flow and its consequent
effects on the amount of amniotic fluid produced for the fetus caused by exposure to losartan, the
fetus is more sensitive to the onset of birth defects.
Physical Signs of Prenatal Losartan Exposure
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Prenatal exposure to losartan is also associated with physical anomalies.
Oligohydramnios increases the chance of the fetal pulmonary and/or skull hypoplasia. The
prolonged lack of amniotic fluid and impairment of the kidneys, associated with inhibition of
RAS, can severely affect lung development by inhibiting lung growth and restricting breathing
(Alwan et al., 2005; Pipkin et al., 1981; Rosenthal & Oparil, 2002; Weber-Schoendorfer et al.,
2020). In skull development, the mechanism by which skull hypoplasia occurs has not been
explained. This condition is characterized by a widened skull or tower skull and is associated
with impaired learning. However, some researchers suggest that the defect originated from
maternal intake of angiotensin receptor blockers, such as losartan, resulting in RAS being
inhibited, and complications due to fetal hypotension and oligohydramnios (Alwan et al., 2005;
Shankar et al., 2019; Weber-Schoendorfer et al., 2020). Fetal growth restriction (FGR) is also a
common outcome of exposure to losartan. FGR is a term used to describe the failure of a fetus to
reach optimal growth in utero, harming overall fetal development. It is usually associated with
incidences of preeclampsia and other events that make an adverse or unsafe prenatal
environment (Bullo et al., 2012; Delforce et al., 2019; Diav-Citrin et al., 2011; Lumbers &
Pringle, 2014; Miremberg et al., 2020; Richter et al., 2020; Rosenthal & Oparil, 2002). The
condition is associated with irregular RAS signaling in the placenta, severe fetal hypotension,
and/or maternal vascular malperfusion lesions. Although the defects involved in this condition
can vary, the main characteristic of FGR is lower birthweight (Delforce et al., 2019; Miremberg
et al., 2020; Rosenthal & Oparil, 2002; Zygula et al., 2020). The fetus could have facial and limb
deformities due to exposure to losartan. These deformities usually arise from cases of
oligohydramnios. For labor, stillbirth and/or pre-term birth is common in fetuses exposed to
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antihypertensive drugs (Alwan et al., 2005). Complications in the baby’s health in later
development due to maternal intake of losartan and other similar medications may also occur.
Specifically, the late onset of medical conditions involving blood pressure and renal perfusion
can occur (Rosenthal & Oparil, 2002). Introducing losartan in the prenatal environment, in turn,
affects multiple organ systems of the body, endangering fetal development and nutrient intake.
Because of its dangerous side-effects for both the mother and the baby, controversial losartan is
not recommended for use during pregnancy.
Opioids
The recent opioid crisis has introduced a new public health issue of opioid-dependency
that is not limited to the pregnant population. Opioids, a category C or D drug, are a class of
drugs derived from opium that is used to treat severe pain by binding to μ-, δ-, and κ-receptors
(Zöllner & Stein, 2007). The opioid epidemic saw drastic growth from 2005-2014; during that
time, opioid-associated hospitalization increased 64%, reaching all parts of the United States
(Lyden & Binswanger, 2019). Correlative to that, opioid abuse among pregnant women became
a prevalent concern. The number of pregnant women using opioids quadrupled from 1999-2014
(Grossman & Berkwitt, 2019). From 2000-2007, one in five American women were prescribed
opioids during pregnancy (Desai et al., 2014). A more recent study reported 6,065 prenatal
hospitalizations due to opioid-related conditions, and 751,037 birth hospitalizations; these
numbers are expected to steadily increase (Hirai et al., 2021). Common opioid use has proven to
be a major concern for fetal development because of the risk of the onset of addiction that is
sometimes undetected.
Codeine and Hydrocodone
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Two of the most common opioids prescribed to pregnant women are codeine (6.1% of
prescribed opioids) and hydrocodone (6.8% of prescribed opioids) (Bateman et al., 2014). The
effects of codeine exposure are inconclusive and difficult to define. Some studies associated
prenatal codeine exposure with congenital cardiac malformation, gastrointestinal anomalies, and
defects in neural tube formation, while other studies found no significant correlation (Bowie et
al., 2022; Fishman et al, 2019; Lind et al., 2017). The trimester during which these drugs are
administered is also vital in understanding its effects (Bowie et al., 2022); however, the severity
of the effects of prenatal opioid exposure in each trimester has not been defined. Codeine is a
major drug interest for research aimed at investigating prenatal opioid use due to its ability to
cross the placenta and be extensively distributed in the tissue. Hydrocodone has been associated
with an increased risk of spina bifida, heart malformations, and club foot (Broussard et al., 2011;
Werler et al., 2014; Yazdy et al., 2013). However, studies focused on hydrocodone exposure
during pregnancy are limited. Opioids are a difficult group of drugs to test due to their common,
unregulated use in over-the-counter medicines, such as cough and cold medications. From an
ethical standpoint, a sufficient sample is also difficult to obtain for these studies. More
longitudinal epidemiological studies need to be conducted to understand the long-term effects of
opioid use during pregnancy.
Neonatal Abstinence Syndrome
One common condition associated with opioid use during pregnancy is neonatal
abstinence syndrome. Habitual maternal use of opioids often leads to infant withdrawal
characterized by blood hypertonicity, poor feeding, tremors, and irritability—a condition called
Neonatal Abstinence Syndrome (NAS). With an increased number of pregnant women who
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regularly intake opioids, the number of infants born with NAS has also increased. The
physiological mechanisms behind the onset of NAS remains unclear. Recent animal studies have
indicated that the onset of withdrawal is different from the adult’s. In gestation, brain
development is highly sensitive, and the growing neurons are still immature. The combination of
developing neurons, levels of opiate receptor-binding, and actions of neurotransmitters occurring
at the same time during fetal development are correlated with withdrawal occurring to the
newborn (Grossman & Berkwitt, 2019; Kinnunen et al., 2019; Kocherlakota, 2014). It is
hypothesized that NAS primarily relies on noradrenergic output of the locus coeruleus which
produces norepinephrine in the pons of the brain. Opiate drugs easily pass through the placenta
due to their low molecular weight and water solubility (lipophilic) (Kocherlakota, 2014). When
µ-opiate receptors are consistently bound to opioids, the locus coeruleus increases production of
cyclic adenosine monophosphate (cAMP) which will activate cAMP-mediated cellular
processes. These processes are essential for maintaining body homeostasis, and with this increase
in cAMP, respond with increased production of norepinephrine. This increase in cellular activity
is hypothesized to be the mechanism of withdrawal symptoms that characterize NAS (Grossman
& Berkwitt, 2019; Kocherlakota, 2014). Additionally, the dopaminergic mesolimbic pathway
decreases dopamine release from the ventral tegmental area into the nucleus accumbens, and the
dorsal raphe nucleus decreases serotonin levels as withdrawal occurs. The symptoms of NAS,
irritability and trouble sleeping, may be associated with these sudden declines (Grossman &
Berkwitt, 2019). The autonomic nervous system can also be affected by NAS. These effects
include changes in breathing rate, unstable body temperature, and skin perfusion which is usually
mistaken for sepsis. In withdrawal, the infant experiences poor feeding, failure to meet the
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caloric needs that hypermetabolism requires. Infants with NAS may also suffer symptoms of
vomiting and diarrhea which complicate their problem with nutritional intake (LaGasse et al.,
2003). These symptoms indicate that the compromised health and postnatal development may be
hindered. However, seizures are the most dangerous outcome of NAS; they are associated with
tremors and sudden jerks (Herzlinger et al., 1977). Moreover, being born into withdrawal is
dangerous and can further delay development that occurs outside the womb.
Other neurological outcomes of opioid exposure include volumetric alterations in
multiple cortical and subcortical regions which are involved in higher-executive functioning,
learning, information-processing, and emotional regulation (Peterson et al., 2020). These effects
imply that cognitive processes may also be affected by opioid exposure. One study found that
white matter integrity and connectivity decreased in the neonatal brain due to opioid exposure
(Monnelly et al., 2018). These cognitive delays may not seem apparent during the first year. A
study by Benninger et al. (2020) found that children who were treated for NAS were at the same
cognitive level as unexposed children during the first year. However, at the second year, exposed
children had significantly lower language and cognitive scores in comparison to the unexposed
children. This finding indicates that the severity of the damage may not be apparent until later in
life. Current research on prenatal opioid exposure is limited due to sample size and an inability to
replicate experiments, especially in human models. However, these findings illustrate that the
opioid exposure during pregnancy places the mother and baby at risk. It is likely that fastidious
drug regulation and testing could prevent the onset of NAS. Yet, a significant number of overthe-counter medications contain opioids. With an increased population of consumers of over-the-
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counter medications containing opioids, education on drug use during pregnancy is required so
that soon-to-be mothers are made well-aware of the risks that opioid exposure may cause.
Alcohol
Prenatal exposure to alcohol (PAE) is one of the leading causes of preventable congenital
conditions (Vorgias & Bernstein, 2021). The CDC (2022) reported that from 2011-2018, alcohol
consumption during pregnancy increased from 9.2% to 11.3% and binge drinking increased from
2.5% to 4.0%. Although the number of individuals affected by fetal alcohol exposure remains
unknown, the CDC found that for every 1,000 live births, 0.2-1.5 infants are born with a fetal
alcohol spectrum disorder. Other environmental/situational factors may affect drinking habits to
varying degrees, and fetal exposure to alcohol can be life-threatening; therefore, alcohol
consumption is discouraged during pregnancy. Alcohol is not categorized and regulated under
the FDA, however for the following review, its prevalent use in pregnant populations is
significant to discuss because of its unregulated use and dangerous side effects on the developing
fetus.
Alcohol is a teratogen that causes permanent damage to the brain and its structures.
During the first trimester, PAE increases the likelihood of physical deformity. High levels of
exposure are associated with occurrences of spontaneous abortion. Decreases in brain volume,
height, and weight result from high levels of exposure during the third trimester (Hasken et al.,
2021; Vorgias & Bernstein, 2021). PAE is also associated with disrupted insulin levels. A study
by Kable, et al. (2021) assessed the intellectual functioning and measured the level of
dysmorphia caused by alcohol exposure of African American adults whose mothers consumed
alcohol and drugs during the first trimester of pregnancy. The researchers found that their insulin

PRENATAL DRUG EXPOSURE

21

levels and body-mass index (BMI) was correlated; individuals who had a BMI below threshold
of overweight or normal had lower insulin levels and higher insulin sensitivity. Moreover,
individuals with above threshold or overweight BMI were more insulin resistant. The researchers
speculate that this relationship between BMI and stage of diabetes development may explain the
increased risk for obesity development with increased insulin sensitivity (Guiducci et al., 2014;
Kable, et al., 2021). Additional research on the cellular development of diabetes in relation to
PAE needs to be conducted, however one group of disorders have been identified due to PAE.
Fetal alcohol spectrum disorders (FASDs) include four main disorders that arise due to alcohol
consumption during pregnancy. This group includes the following disorders: fetal alcohol
syndrome (FAS), partial fetal alcohol syndrome (PFAS), static encephalopathy/alcohol exposed
(SE/AE), and neurobehavioral disorder/alcohol exposed (ND/AE).
Fetal Alcohol Spectrum Disorders
FAS is a permanent birth defect that is characterized by minor abnormalities of the face,
central nervous system (CNS) or brain, and prenatal and/or postnatal growth deficiency. For this
disorder to be diagnosed, the presence of all three characteristics is necessary (Davies, 2021).
This growth restriction of the fetus can manifest as low birthweight, being small for their
gestational age, and failure to thrive. In a study of children in South Africa, in comparison to
children with PFAS, children with FAS were reported to be lighter, more dysmorphic, and
shorter in height (Hasken et al., 2021). These physical signs of FAS differentiate this disorder
from the FASDs. Facial characteristics of children with FAS and PFAS include a smaller smooth
philtrum, narrower vermilion, and smaller maxillary and mandibular arcs in addition to their
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short stature (May et al., 2020). FAS, therefore, is a condition that describes permanent physical
abnormalities in comparison to the partial and/or mainly neural damage present in other FASDs.
PFAS has similar physical cranial anomalies as FAS. The major difference is that PFAS
does not consist of all the physical manifestations of FAS; children with PFAS either have
moderate facial structures or do not have impaired growth (Davies, 2021). Notably, the facial
features resulting from FAS and PFAS, specifically, were found to evolve or slightly diminish as
the child aged in one study and indicate inhibited forebrain development (Jacobson et al., 2020).
Additionally, neural damage is common for both cases of FAS and PFAS.
SE/AE is the condition in which there is evidence of structural damage in the brain and/or
severe neural dysfunction. Individuals with this condition usually have a smaller head
circumference or cranial structure abnormality. Their severe brain damage results in the onset of
a seizure disorder and/or hard neurological signs of damage. The CNS experiences significant
damage due to this condition in three or more parts of the brain (Darbinian et al., 2021; Davies,
2021). In prenatal ethanol exposure cases, the oligodendrocyte cell populations experience
inhibited growth, slowing the process of maturation and affecting apoptosis (Darbinian et al.,
2021). In the future, research should focus on the relationship between the occurrence of
apoptosis and SE/AE to understand this inhibiting effect in brain maturation.
Individuals with ND/AE have a moderate dysfunction that suggests possible CNS
damage. The dysfunction apparent in this condition is primarily identified interview data,
observational study, and other psychological/psychometric tests. The level of damage occurs in
either one or two domains (Davies, 2021). These critical, four main FASDs are also associated
with cognitive impairment and other physiological complications that can develop postnatally
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reaching adulthood for those who are diagnosed with one of the disorders. Therefore, more
studies focused on each of the FASDs is required to determine the pathways and physiological
changes associated with each disorder.
The actual mechanism behind FASDs has not been determined, however there are
significant neurological effects associated with FASDs that may develop into the onset of other
disorders/disabilities. A major part of the development of these disorders involves brain
dysmyelination, affecting the concentration of white matter in the brain. Microglia in the CNS
play a role in the immune response and maintenance of homeostasis. They perform phagocytosis,
antigen reception, and the production of cytokines and chemokines; overall, microglia remove
pathogens that can damage cells of the CNS (Kane & Drew, 2020; Ransohoff & Brown, 2012).
When microglia are exposed to ethanol, a set of downstream signaling pathways resulting in
microglial activation whereby oxygenated species are produced, and the neurons undergo
apoptosis. In rodent and human FAS studies, apoptosis of oligodendrocyte precursor cells and
repressed differentiation of oligodendrocytes occurred, accompanied by reduced or delayed
myelin production. This phenomenon results in synaptic loss, leading to the onset of fatal
FASDs (Darbinian et al., 2021; Kane & Drew, 2020). The postnatal, early stage of rodents is
equivalent to the third trimester of human pregnancy. When ethanol is introduced during this
period, increased expression of certain chemokines (CCL2 and CCL4), which function in
directing white blood cell activity, and pro-inflammatory cytokines (TNF-α and IL-1β), which
function in chemical messaging, were found to be involved in this process of demyelination as
the structure of the hippocampus was altered (Niedzwiedz-Massey et al., 2021). The dysfunction
of cytokines and chemokines in the brain through ethanol exposure induces neuroinflammation.
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Moreover, the white matter development in the brain is negatively affected. White matter is
heavily involved in learning and other executive brain functions. It is an area of the brain that has
high connectivity and is known for its large concentration of myelin. FASDs and ethanol
exposure are significantly correlated with less white matter in the brain (Darbinian et al., 2021;
Kane & Drew, 2020; Niedzwiedz-Massey et al., 2021; Stephen et al., 2021). Less white matter
also entails less myelin. Myelin is a lipid-rich sheath originating from the oligodendrocytes and
surround axons; it functions in communication between neurons. Therefore, if there is less
myelin, communication between neurons is impaired which translates into cognitive disabilities
and poor adaptive ability (Brown & Reynolds, 2021; Niedzwiedz-Massey et al., 2021). The
consequence of alcohol exposure disturbs appropriate executive function, resulting in the
development of emotional and behavioral disorders. Children with white matter abnormality also
have impaired connectivity between the hemispheres of the brain, inhibiting efficient flow of
information (Stephen et al., 2021). Impaired connectivity affects reasoning, memory, and other
skills required as the child begins to attend school and learn. This brain damage can, therefore,
develop into learning disorders, autism spectrum disorders, and other difficulties in cognitive
ability as a child continues to develop postnatally (Brown & Reynolds, 2021; Khalifa et al.,
2021; Stephen et al., 2021). Furthermore, prenatal exposure to alcohol has far-reaching effects as
the child grows that can extend to postnatal development and evolve into serious behavioral
disorders.
The mechanism by which alcohol affects fetal development and determines occurrence of
FASDs is still being researched. One study by Fischer et al. (2021) used in vitro human
pluripotent stem cells as a model of corticogenesis to understand the molecular and genetic
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mechanisms behind development of FAS. The cortical neurons were exposed to 50 mM ethanol
for 50 days. The researchers identified that pathways involved in cell specification, axon and
synapse differentiation and growth, and gene patterns were affected, specifically the WNT
signaling pathway. A shift in gene expression caused the genes involved with caudal forebrain
formation and growth to be upregulated in comparison to the anterior (Fischer et al., 2021). Their
findings indicate that the effect of alcohol on fetal development is widespread; furthermore,
prenatal alcohol exposure, if not prevented, may be more dangerous to the overall development
of the fetus. Further research is required to understand the long-term effects of alcohol exposure
on development, however finding a sufficient sample and producing longitudinal
epidemiological studies have become a challenge in studying the occurrence of FASDs.
Caffeine
The most widely used drug in the world is caffeine. Caffeine is a stimulant that induces
wakefulness. It is commonly found in coffee, teas, and other beverages. Caffeine is also widely
used by women during pregnancy; however, it is not regulated by the FDA and does not have a
classification (Mioranzza et al., 2014). Caffeine is an antagonist to the A1 and A2 adenosine
receptors that will become G-protein coupled during the postnatal stage in the cortex and
hippocampus. This stimulant can easily pass through the fetal brain and placental barrier. Rodent
model studies on caffeine revealed that mice exposed to high dosages of caffeine, equivalent to
6-12 cups of coffee for a human being, experienced delayed conception and placenta weight;
furthermore, there was an increased risk for intrauterine growth retardation, fetal resorption, and
low birth weight. Female rats who were not pregnant were exposed to the same dosage of
caffeine for four days and subsequently experienced reduced fertility due to disrupted embryo
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implantation (Huang et al. 2012; Pollard et al., 1999; Qian et al., 2020). In addition, neural tube
growth was inhibited in the presence of caffeine (Jacombs et al., 1999). This finding implies that,
due to neural tube growth being prevented, the formation and development of the brain and
spinal cord is delayed for which the neural tube is the basis. In rat models, prenatal exposure to
caffeine increased the frequency of physical malformations of the limbs and palate. High doses
of the drug used on mother rats was correlated with growth retardation, skull structure
abnormality, and fetal death (Brent et al., 2011). Although findings on growth retardation due to
caffeine is similar for both animal and human studies, the effects of caffeine on human fetal
development, especially in prenatal and postnatal brain development, is poorly researched. The
human studies on prenatal caffeine exposure are inconclusive due to small sample sizes and
failures to account for other variables (Brent et al., 2011; Schmidt et al., 2009). The results of
animal studies cannot be ultimately used to understand the effects of caffeine exposure on human
fetal development. Future studies will need to focus on human populations to establish clinical
significance. Furthermore, if conducted accurately and ethically, future research should attempt
to explain the mechanism by which caffeine directly causes birth defects. For the present
pregnant population, ongoing studies on caffeine and other stimulants should increase awareness
and serve as a basis of extreme caution for prenatal drug use.
Implications for Pharmaceutical Procedures and Pregnant Women
The sensitive period of pregnancy is characterized by the development of essential organ
systems. Each stage of development heavily interacts with the mother and relies on the ability of
the body to maintain conditions that are most conducive to the successful growth and
development of the baby in the womb. Furthermore, as the population of pregnant women with
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underlying health conditions increases and more medications are prescribed to relieve the
outcomes of being pregnant, prescription and over-the-counter drug usage has increased as well.
From past events, the scientific community has witnessed the mass effects of lenient drug testing
and regulation, especially on pregnant women and their offspring. As seen with the case of
thalidomide, drug regulation became a primary concern for the safety of both the mother and the
developing fetus. This issue was addressed by the FDA with their labelling systems; however,
this solution has become a cause of confusion for mothers and the medical personnel involved.
Clarification of these labels was established, however due to the urgency of the issue at hand, a
faster solution is required to maintain the maternal and fetal health.
The development of more educational programs that target pregnant/lactating women
should be developed to increase awareness of drug use during pregnancy and its risks and
benefits, especially for women with underlying health conditions. Although programs that serve
to assist mothers suffering from drug addiction or alcoholism are established, education on
common drugs, such as opioids and losartan, that are used to treat a variety of
symptoms/illnesses and are easily accessible is lacking in the United States. In a clinical setting,
a soon-to-be mother may not fully understand the risks of certain medications and make hasty
health decisions. Programs that aim to teach pregnant women the importance of maintaining their
physical health and being involved in communication with their doctor would empower them to
make the best medical judgment for them and their children.
The increasingly common use of drugs to treat a variety of symptoms and conditions
requires researchers to urgently test and study the effects of prolonged usage of these drugs on
target populations. Unregulated drugs, such as caffeine, have been found to cause detrimental
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developmental delay in utero in rodent and human studies (Brent et al., 2011; Huang et al. 2012;
Jacombs et al., 1999; Pollard et al., 1999; Qian et al., 2020). Longitudinal effects of caffeine
intake on pregnancy outcomes require more research, yet the current findings are pointing
towards possible health complications in fertility, implantation, and organogenesis that can affect
the outcome of the pregnancy and development of the fetus. Thus, this trend in the literature
indicates that unregulated and/or addictive drugs are also important future research topics, as
seen with the studies on alcohol. Pregnant women are a highly sensitive population. The
clinicians that serve this group are challenged with maintaining the mother’s physical health
necessary for the baby’s normal development and/or developing a treatment plan for any current
health issue she may be experiencing without jeopardizing her pregnancy. Because pregnancy
involves both the mother and the child, more research on both regulated and unregulated drugs
used by pregnant and lactating women needs to be conducted so that clinicians can better inform
mothers on how to best approach their current health status. Epidemiological research on the
prolonged effects of these common drugs will be beneficial for educational programs in better
informing future mothers. Though research in this field has improved over the years, limitations
in experimental methods are still apparent. Finding sufficient samples, producing controlled
studies, and following ethical standards are vital to gain significant findings. Moreover,
longitudinal research studies are the most suitable in understanding the health risks associated
with prenatal drug exposure. The critical period of pregnancy that drug exposure may cause
more severe outcomes in has not been determined. Future research should focus on the trimester
in which fetal development is the most sensitive to drug exposure specific to each drug. The
literature, then, on this subject can expand to determining the molecular/cellular pathways in
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utero that are affected by these drugs. Furthermore, with this in-depth understanding, clinicians
and mothers are able to make more well-informed health decisions that will be able to preserve
the optimal conditions for normal pregnancy to occur and proceed.
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Appendix A

FDA Drug Classification by Letter Category and New Label.
Drug

Letter

New Label

Category
Thalidomide

X

Pregnancy Exposure Registry
There is a pregnancy exposure registry that monitors pregnancy outcomes
in females exposed to THALOMID during pregnancy as well as female
partners of male patients who are exposed to THALOMID. This registry
is also used to understand the root cause for the pregnancy. Report any
suspected fetal exposure to THALOMID to the FDA via the MedWatch
program at 1-800-FDA-1088 and to Celgene Corporation at 1-888-4235436.
Risk Summary
Based on the mechanism of action [see Clinical Pharmacology (12.1)],
human and animal data (see Data), THALOMID can cause embryo-fetal
harm when administered to a pregnant female and is contraindicated
during pregnancy [see Boxed Warning, Contraindications (4.1), and
Warnings and Precautions (5.1)]. THALOMID is a human teratogen,
inducing a high frequency of severe and life-threatening birth defects such
as amelia (absence of limbs), phocomelia (short limbs), hypoplasticity of
the bones, absence of bones, external ear abnormalities (including anotia,
micropinna, small or absent external auditory canals), facial palsy, eye
abnormalities (anophthalmos, microphthalmos), and congenital heart
defects. Alimentary tract, urinary tract, and genital malformations have
also been documented and mortality at or shortly after birth has been
reported in about 40% of infants. Even a single dose taken by a pregnant
woman can cause birth defects. If this drug is used during pregnancy, or if
the patient becomes pregnant while taking this drug, the patient should be
apprised of the potential risk to a fetus. If pregnancy does occur during
treatment, immediately discontinue the drug. Under these conditions,
refer the patient to an obstetrician/gynecologist experienced in
reproductive toxicity for further evaluation and counseling. Report any
suspected fetal exposure to THALOMID to the FDA via the MedWatch
program at 1-800-FDA1088 and also to Celgene Corporation at 1-888423-5436. Thalidomide crossed the placenta after administration to
pregnant hamsters (see Data). The estimated background risk of major
birth defects and miscarriage for the indicated population is unknown. All
pregnancies have a background risk of birth defect, loss, or other adverse
outcomes. The estimated background risk in the U.S. general population
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of major birth defects is 2%-4% and of miscarriage is 15%-20% of
clinically recognized pregnancies.
Data
Animal Data
A pre- and postnatal reproductive toxicity study was conducted in
pregnant female rabbits. Compound-related increased abortion incidences
and elevated fetotoxicity were observed at the lowest oral dose level of 30
mg/kg/day (approximately 1.5-fold the maximum human dose based upon
BSA) and all higher dose levels. Neonatal mortality was elevated at oral
dose levels to the lactating female rabbits ≥150 mg/kg/day (approximately
7.5-fold the maximum human dose based upon BSA). No delay in
postnatal development, including learning and memory functions, were
noted at the oral dose level to the lactating female rabbits of 150
mg/kg/day (average thalidomide concentrations in milk ranged from 22 to
36 mcg per mL). In a study conducted in pregnant rabbits, thalidomide
levels in fetal plasma were approximately 11% to 73% of the maternal
Cmax. In a study conducted with 14C-thalidomide (150 mg/kg orally) in
pregnant hamsters, radioactivity was detected in the embryo, and the
relative concentrations of radioactivity in the embryo and maternal plasma
were about the same at 4, 12 and 24 hours after dosing. Based on the
radioactivity data, thalidomide crossed the placental barrier, and the fetal
levels of drug-related material were approximately similar to those of
maternal levels.1
Losartan

C or D

COZAAR can cause fetal harm when administered to a pregnant woman.
Use of drugs that act on the reninangiotensin system during the second
and third trimesters of pregnancy reduces fetal renal function and
increases fetal and neonatal morbidity and death. Most epidemiologic
studies examining fetal abnormalities after exposure to antihypertensive
use in the first trimester have not distinguished drugs affecting the
reninangiotensin system from other antihypertensive agents. When
pregnancy is detected, discontinue COZAAR as soon as possible (see
Clinical Considerations). The estimated background risk of major birth
defects and miscarriage for the indicated population is unknown. All
pregnancies have a background risk of birth defect, loss, or other adverse
outcomes. In the U.S. general population, the estimated background risk
of major birth defects and miscarriage in clinically recognized
pregnancies is 2% to 4% and 15% to 20%, respectively.
Clinical Considerations Disease-associated
Maternal and/or Embryo/Fetal Risk
Hypertension in pregnancy increases the maternal risk for pre-eclampsia,
gestational diabetes, premature delivery, and delivery complications (e.g.,
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need for cesarean section, post-partum hemorrhage). Hypertension
increases the fetal risk for intrauterine growth restriction and intrauterine
death. Pregnant women with hypertension should be carefully monitored
and managed accordingly.
Fetal/Neonatal Adverse Reactions
Oligohydramnios in pregnant women who use drugs affecting the reninangiotensin system in the second and third trimesters of pregnancy can
result in the following: reduced fetal renal function leading to anuria and
renal failure, fetal lung hypoplasia, skeletal deformations, including skull
hypoplasia, hypotension, and death. In the unusual case that there is no
appropriate alternative to therapy with drugs affecting the
reninangiotensin system for a particular patient, apprise the mother of the
potential risk to the fetus. In patients taking COZAAR during pregnancy,
perform serial ultrasound examinations to assess the intraamniotic
environment. Fetal testing may be appropriate, based on the week of
gestation. If oligohydramnios is observed, discontinue COZAAR, unless
it is considered lifesaving for the mother. Patients and physicians should
be aware, however, that oligohydramnios may not appear until after the
fetus has sustained irreversible injury. Closely observe neonates with
histories of in utero exposure to COZAAR for hypotension, oliguria, and
hyperkalemia. In neonates with a history of in utero exposure to
COZAAR, if oliguria or hypotension occurs, support blood pressure and
renal perfusion. Exchange transfusions or dialysis may be required as a
means of reversing hypotension and replacing renal function.
Data
Animal Data
Losartan potassium was administered orally to rats during the period of
late gestation through lactation (Gestation Day 15 through Lactation Day
20) at doses of 10, 25, and 100 mg/kg/day. Losartan potassium has been
shown to produce adverse effects in rat fetuses and neonates, including
decreased body weight, delayed physical and behavioral development,
mortality and renal toxicity. With the exception of neonatal weight gain
(which was affected at doses as low as 10 mg/kg/day), doses associated
with these effects exceeded 25 mg/kg/day (approximately three times the
maximum recommended human dose of 100 mg on a mg/m2 basis).
These findings are attributed to drug exposure in late gestation and during
lactation. Significant levels of losartan and its active metabolite were
shown to be present in rat fetal plasma during late gestation and in rat
milk.2
Alcohol

N/A

N/A

PRENATAL DRUG EXPOSURE
Opioids

47

B; D for

Risk Summary:
Prolonged use of opioid analgesics during pregnancy may cause neonatal
prolonged opioid withdrawal syndrome [see Warnings and Precautions (5.5)].
Available data with Codeine Sulfate Tablets are insufficient to inform a
use
drug-associated risk for major birth defects and miscarriage. In animal
reproduction studies, codeine administration during organogenesis has
been shown to produce delayed ossification in the offspring of mice at 1.4
times maximum recommended human dose (MRHD) of 360 mg/day,
embryolethal and fetotoxic effects in the offspring of rats and hamsters at
approximately 2 to 3 times the MRHD, and cranial
malformations/cranioschisis in the offspring of hamsters between 2 and 8
times the MRHD [see Data]. All pregnancies have a background risk of
birth defect, loss, or other adverse outcomes. In the U.S. general
population, the estimated background risk of major birth defects and
miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to
20%, respectively.
Clinical Considerations:
Fetal/Neonatal Adverse Reactions: Prolonged use of opioid analgesics
during pregnancy for medical or nonmedical purposes can result in
physical dependence in the neonate and neonatal opioid withdrawal
syndrome shortly after birth.
Neonatal opioid withdrawal syndrome presents as irritability,
hyperactivity and abnormal sleep pattern, high pitched cry, tremor,
vomiting, diarrhea, and failure to gain weight. The onset, duration, and
severity of neonatal opioid withdrawal syndrome vary based on the
specific opioid used, duration of use, timing and amount of last maternal
use, and rate of elimination of the drug by the newborn. Observe
newborns for symptoms of neonatal opioid withdrawal syndrome and
manage accordingly [see Warnings and Precautions (5.5)].
Labor or Delivery: Opioids cross the placenta and may produce
respiratory depression and psycho-physiologic effects in neonates. An
opioid antagonist, such as naloxone, must be available for reversal of
opioid-induced respiratory depression in the neonate. Codeine Sulfate
Tablets are not recommended for use in pregnant women during or
immediately prior to labor, when other analgesic techniques are more
appropriate. Opioid analgesics, including Codeine Sulfate Tablets, can
prolong labor through actions which temporarily reduce the strength,
duration, and frequency of uterine contractions. However, this effect is
not consistent and may be offset by an increased rate of cervical dilation,
which tends to shorten labor. Monitor neonates exposed to opioid
analgesics during labor for signs of excess sedation and respiratory
depression. Reference ID: 4756502
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Data:
Animal Data: Studies on the reproductive and developmental effects of
codeine have been reported in the published literature in hamsters, rats,
mice and rabbits. In a study in which pregnant hamsters were
administered 150 mg/kg twice daily of codeine (oral; approximately 7
times the maximum recommended daily dose of 360 mg/day for adults on
a mg/m2 basis) during organogenesis cranial malformations (i.e.,
meningoencephalocele) in several fetuses were reported; as well as the
observation of increases in the percentage of resorptions per litter. Doses
of 50 and 150 mg/kg, bid resulted in fetotoxicity as demonstrated by
decreased fetal body weight. In an earlier study in hamsters, single oral
doses of 73 to 360 mg/kg level on Gestation Day 8 (oral; approximately 2
to 8 times the maximum recommended daily dose of 360 mg/day for
adults on a mg/m2 basis), reportedly produced cranioschisis in all of the
fetuses examined. In studies in rats, doses at the 120 mg/kg level (oral;
approximately 3 times the maximum recommended daily dose of 360
mg/day for adults on a mg/m2 basis) during organogenesis, in the toxic
range for the adult animal, were associated with an increase in embryo
resorption at the time of implantation. In pregnant mice, a single 100
mg/kg dose (subcutaneous; approximately 1.4 times the recommended
daily dose of 360 mg/day for adults on a mg/mg2 basis) administered
between Gestation Day 7 and 12 reportedly resulted in delayed
ossification in the offspring. No teratogenic effects were observed in
rabbits administered up to 30 mg/kg (approximately 2 times the maximum
recommended daily dose of 360 mg/day for adults on a mg/m2 basis) of
codeine during organogenesis. Codeine (30 mg/kg) administered
subcutaneously to pregnant rats during pregnancy and for 25 days after
delivery increased neonatal mortality at birth. This dose is 0.8 times the
maximum recommended human dose of 360 mg/day on a body surface
area comparison.3
Caffeine

N/A

N/A

Note. The following table describes the letter category and the section of the label discussing
pregnancy risks as established by the FDA for the drugs described in this review.
1
The following description is of Thalomid
(https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020785s069lbl.pdf)
2
The following description is of Cozaar.
(https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020386s064lbl.pdf)
3
The following description is of Codeine Sulfate.
(https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022402s014lbl.pdf)

